Myla Puyat
Directeur Financier/CFO chez Auxogyn, Inc.
Profil
Ms. Myla Puyat is Vice President-Finance & Administration at Auxogyn, Inc. and Vice President-Finance & Administration at Progyny, Inc.
Ms. Puyat was previously employed as a Director-Finance & Administration by ForteBio, Inc., Operations Director & Controller by GeneTrol Biotherapeutics, Inc., and Vice President-Finance & Administration by Verinata Health, Inc.
She received her undergraduate degree from Santa Clara University and an MBA from Santa Clara University.
Postes actifs de Myla Puyat
| Sociétés | Poste | Début |
|---|---|---|
Auxogyn, Inc.
 Auxogyn, Inc. BiotechnologyHealth Technology Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA. | Directeur Financier/CFO | 01/07/2014 |
Anciens postes connus de Myla Puyat
| Sociétés | Poste | Fin |
|---|---|---|
| PROGYNY, INC. | Directeur Financier/CFO | - |
ForteBio, Inc.
 ForteBio, Inc. Medical SpecialtiesHealth Technology Pall ForteBio Corp. develops analytical systems that enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The company was founded in October 2001 and is headquartered in Menlo Park, CA. | Directeur Financier/CFO | - |
| GeneTrol Biotherapeutics, Inc. | Directeur des opérations | - |
Verinata Health, Inc.
 Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Directeur Financier/CFO | - |
Formation de Myla Puyat
| Santa Clara University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PROGYNY, INC. | Commercial Services |
| Entreprise privées | 4 |
|---|---|
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Health Services |
ForteBio, Inc.
ForteBio, Inc. Medical SpecialtiesHealth Technology Pall ForteBio Corp. develops analytical systems that enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The company was founded in October 2001 and is headquartered in Menlo Park, CA. | Health Technology |
| GeneTrol Biotherapeutics, Inc. | |
Auxogyn, Inc.
Auxogyn, Inc. BiotechnologyHealth Technology Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA. | Health Technology |